NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Fulcrum Therapeutics, Inc. (FULC) Stock Analysis

Fulcrum Therapeutics, Inc. (FULC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FULC

$3.85

+$0.01 (+0.26%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FULC with… →

FULC Key Statistics

As of Sep 4, 2026
Trading
Open
$3.81
Previous Close
$3.84
Day's Range
3.80–3.86
52-Week Range
2.83–15.74
Volume
1.00M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.58
Valuation
Market Cap
$293.74M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.21
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$74.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.30M
1-Year Return
−44.04%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
2.23M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FULC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.96%
2025+140.64%
2024−30.37%
2023−7.28%
2022−58.85%
2021+51.07%
2020−29.63%
2019 (partial year)+23.26%

As of September 4, 2026.

FULC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$74.88M—
2024$80.00M−$9.73M−12.2%
2023$2.81M−$97.34M−3470.1%
2022$6.34M−$109.87M−1732.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.77M−$74.88M—
2024$80.00M—−$19.83M−$9.73M−12.2%
2023$2.81M—−$110.66M−$97.34M−3470.1%
2022$6.34M—−$112.13M−$109.87M−1732.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FULC Valuation vs Biotechnology Median

Median of 656 stocks
MetricFULCBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Fulcrum Therapeutics, Inc. (FULC) is capitalised at $293.74M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 9 employees.

Over the past 52 weeks the price has ranged from $2.83 to $15.74. The most recent close on file for FULC is $3.85, dated September 4, 2026. That is +$0.01 (+0.26%) against the previous close. The latest close sits 36.04% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $80.00M. The same year closed with a net loss of $74.88M. Profit margin runs at 0%. Trailing earnings per share are −1.21.

Across the 4 fiscal years on file, revenue moves from $6.34M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.59. Daily returns over the trailing 7 years annualize to a volatility of 110.24%. The trailing one-year price return is −44.04%. Measured over 5 years, that is −32.79% a year compounded.

Growth & Income

The record shows no dividend for FULC.

The strongest complete calendar year on file is 2025 at +140.64%; the weakest is 2022 at −58.85%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −65.96% year to date.

Peer Comparison

Fulcrum Therapeutics, Inc. (FULC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fulcrum Therapeutics, Inc. FULC $293.74M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Fulcrum Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit website →